<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361581</url>
  </required_header>
  <id_info>
    <org_study_id>NS/10014-4</org_study_id>
    <nct_id>NCT01361581</nct_id>
  </id_info>
  <brief_title>Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy</brief_title>
  <acronym>Citrate</acronym>
  <official_title>Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Citrate anticoagulation is associated with metabolic side effects which are linked to a
      portion of citrate reaching systemic circulation. Data on significance of systemic gain of
      citrate and its relationship to method configuration are missing. Patient might also receive
      certain dose of lactate as a buffer and a dose of glucose if acid-citrate-dextrose solution
      is used. The authors test variable methods of indirect estimate of systemic dose of citrate
      which would allow to quantify the metabolic input without mostly unavailable measurements of
      citrate levels.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Renal Failure</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>ACD (acid-citrate-dextrose)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>4% trisodium citrate</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>unfractionated heparin (UFH)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        critically ill intensive care patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute renal failure on continuous renal replacement therapy for more than 24 hours
             (CVVH or CVVHDF).

        Exclusion Criteria:

          -  Absence of consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Anaesthesia and Intensive Care, General University Hospital, 1st Medical Faculty, Charles University</name>
      <address>
        <city>Prague 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Balik, A/Prof</last_name>
      <email>martin.balik@post.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Balik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Martin Balik, A/Prof., MD, PhD, EDIC</name_title>
    <organization>1st Medical Faculty, Charles University, Prague</organization>
  </responsible_party>
  <keyword>Acute renal failure</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Citrate</keyword>
  <keyword>Haemodiafiltration</keyword>
  <keyword>Haemofiltration</keyword>
  <keyword>Renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

